ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory Analysis
本文未提供摘要,请点击“查看全文”查看完整内容。